{"filing":{"accession_number":"0001213900-26-065294","cik":"0000907654","ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"ea0293648-8k_oruka.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/907654/000121390026065294/ea0293648-8k_oruka.htm"},"events":[{"id":6854,"run_id":6005,"accession_number":"0001213900-26-065294","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 filing discloses the results of Oruka Therapeutics' Annual Meeting of Stockholders held on June 2, 2026, with detailed vote tallies for three proposals: election of two Class II directors (Lawrence Klein and Chris Martin), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents the complete voting results including shares voted for/against, abstentions, and broker non-votes for each matter, which is the core disclosure required under Item 5.07.","company_name":"Oruka Therapeutics, Inc.","ticker":"ORKA","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4390,"accession_number":"0001213900-26-065294","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of Oruka Therapeutics' Annual Meeting of Stockholders held on June 2, 2026, with detailed vote tallies for three proposals: election of two Class II directors (Lawrence Klein and Chris Martin), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents the complete voting results including shares voted for/against, abstentions, and broker non-votes for each matter, which is the core disclosure required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:16:52.267661+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4390,"accession_number":"0001213900-26-065294","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of Oruka Therapeutics' Annual Meeting of Stockholders held on June 2, 2026, with detailed vote tallies for three proposals: election of two Class II directors (Lawrence Klein and Chris Martin), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents the complete voting results including shares voted for/against, abstentions, and broker non-votes for each matter, which is the core disclosure required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:16:52.267661+00:00","company_name":"Oruka Therapeutics, Inc.","ticker":"ORKA","filing_date":"2026-06-04"}]}